28Aug 2023
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer

Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer

The study identified a serum biomarker that could predict treatment outcomes for metastatic prostate cancer patients receiving Abiraterone (Abi). The study analyzed protein profiles of sensitive and resistant cell lines, identifying elevated FSCN1 levels linked to poorer survival in Abi-treated patients. The finding suggests that FSCN1 could be a prognostic marker for Abi therapy, aiding personalized treatment strategies. The study also revealed no similar link in Docetaxel-treated patients. This breakthrough could improve patient care and enhance prostate cancer management.

  • #oncology

Like

Save

Share